artelo biosciences

Greg Gorgas, President & CEO of Artelo Biosciences (NASDAQ: ARTL), was recently a guest on Benzinga’s All-Access. Artelo is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways...

Artelo Biosciences, Inc. (NASDAQ: ARTL) announced that Professor Saoirse O’Sullivan, vice president of Translational Sciences at Artelo, presented new data at the International Cannabinoid Research Society (ICRS) Symposium in Ontario, CA, highlighting the pharmaceutical properties and...

Artelo Biosciences (NASDAQ: ARTL) announced its third-quarter results as of May 31.  The La Jolla, California-based company reported a net loss of $951,191, approximately $0.27 per basic share in contrast to $0.17 per share for the same quarter 2019. Operating expenses related to research...